In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund; Michael Tveden Gundesen; Annette Juul Vangsted; Carsten Helleberg; Einar Haukås; Trine Silkjær; Jon Thor Asmussen; Elena Manuela Teodorescu; Bo Amdi Jensen; Tobias Schmidt Slørdahl; Hareth Nahi; Anders Waage; Niels Abildgaard; Fredrik Schjesvold; Nordic Myeloma Study Group

doi:10.1038/s41408-024-01046-2

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund^*, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Nordic Myeloma Study Group

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

14 Downloads (Pure)

Original language	English
Article number	65
Journal	Blood Cancer Journal
Volume	14
Issue number	1
Number of pages	5
DOIs	https://doi.org/10.1038/s41408-024-01046-2
Publication status	Published - 15 Apr 2024

Keywords

Humans
Zoledronic Acid/therapeutic use
Multiple Myeloma/drug therapy
Diphosphonates/therapeutic use
Bone Diseases/drug therapy
Bone and Bones
Bone Neoplasms
Bone Density Conservation Agents/therapeutic use

Access to Document

10.1038/s41408-024-01046-2Licence: CC BY 4.0

Lund et al. (2024). In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone diseaseFinal published version, 796 KBLicence: CC BY 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Lund, T., Gundesen, M. T., Juul Vangsted, A., Helleberg, C., Haukås, E., Silkjær, T., Asmussen, J. T., Manuela Teodorescu, E., Amdi Jensen, B., Schmidt Slørdahl, T., Nahi, H., Waage, A., Abildgaard, N., Schjesvold, F., & Nordic Myeloma Study Group (2024). In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood Cancer Journal, 14(1), Article 65. https://doi.org/10.1038/s41408-024-01046-2

@article{a31bb571b6934a2baa1c7540c04d8028,

title = "In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease",

keywords = "Humans, Zoledronic Acid/therapeutic use, Multiple Myeloma/drug therapy, Diphosphonates/therapeutic use, Bone Diseases/drug therapy, Bone and Bones, Bone Neoplasms, Bone Density Conservation Agents/therapeutic use",

author = "Thomas Lund and Gundesen, {Michael Tveden} and {Juul Vangsted}, Annette and Carsten Helleberg and Einar Hauk{\aa}s and Trine Silkj{\ae}r and Asmussen, {Jon Thor} and {Manuela Teodorescu}, Elena and {Amdi Jensen}, Bo and {Schmidt Sl{\o}rdahl}, Tobias and Hareth Nahi and Anders Waage and Niels Abildgaard and Fredrik Schjesvold and {Nordic Myeloma Study Group}",

year = "2024",

month = apr,

day = "15",

doi = "10.1038/s41408-024-01046-2",

language = "English",

volume = "14",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

Lund, T, Gundesen, MT, Juul Vangsted, A, Helleberg, C, Haukås, E, Silkjær, T, Asmussen, JT, Manuela Teodorescu, E, Amdi Jensen, B, Schmidt Slørdahl, T, Nahi, H, Waage, A, Abildgaard, N, Schjesvold, F & Nordic Myeloma Study Group 2024, 'In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease', Blood Cancer Journal, vol. 14, no. 1, 65. https://doi.org/10.1038/s41408-024-01046-2

TY - JOUR

T1 - In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

AU - Lund, Thomas

AU - Gundesen, Michael Tveden

AU - Juul Vangsted, Annette

AU - Helleberg, Carsten

AU - Haukås, Einar

AU - Silkjær, Trine

AU - Asmussen, Jon Thor

AU - Manuela Teodorescu, Elena

AU - Amdi Jensen, Bo

AU - Schmidt Slørdahl, Tobias

AU - Nahi, Hareth

AU - Waage, Anders

AU - Abildgaard, Niels

AU - Schjesvold, Fredrik

AU - Nordic Myeloma Study Group

PY - 2024/4/15

Y1 - 2024/4/15

KW - Humans

KW - Zoledronic Acid/therapeutic use

KW - Multiple Myeloma/drug therapy

KW - Diphosphonates/therapeutic use

KW - Bone Diseases/drug therapy

KW - Bone and Bones

KW - Bone Neoplasms

KW - Bone Density Conservation Agents/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85190364394&partnerID=8YFLogxK

U2 - 10.1038/s41408-024-01046-2

DO - 10.1038/s41408-024-01046-2

M3 - Letter

C2 - 38622134

SN - 2044-5385

VL - 14

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 65

ER -

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Keywords

Access to Document

AUB Link

Other files and links

Cite this